Switzerland· 65695002
Synagis 100 mg/1 ml, Injektionslösung
A palivizumab product containing palivizumabum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- Switzerland: $51.40 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
Swissmedic (Switzerland)- Active substance
- palivizumabum
- Manufacturer
- AstraZeneca AG
- Country
- Switzerland (CH)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680656950022Durchstf 1 StkCHF 1025.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwaySynagisAstraZeneca
- CzechiaSYNAGISAstraZeneca AB, Södertälje
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- BelgiumSynagis 100 mg/mlAstraZeneca
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- IcelandSynagisAstraZeneca AB*
- PolandSynagisAstraZeneca AB
- FinlandSynagisOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f10afb6e-e349-4084-a5c5-3bce1ffc932b GET /v1/drugs/f10afb6e-e349-4084-a5c5-3bce1ffc932b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "palivizumabum 100 mg",
"valid_from": "2017-08-01",
"limitations": "[{\"description\":\"Die Kostenübernahme von Synagis als Teil einer präventiven Massnahme im Rahmen der obligatorischen Krankenpflegeversicherung richtet sich nach den in Artikel 12b KLV für Synagis abschliessend festgelegten Voraussetzungen.<br>\\nDurch die COVID-19 Pandemie kann die RSV-Saison verzögert eintreten – dieser Umstand soll eine Kostenübernahme durch den Krankenversicherer nicht behindern.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2022-10-01\"}]",
"galenic_form": "Inj Lös 100 mg/1ml",
"therapeutic_area": null,
"sl_inclusion_date": "2017-08-01",
"self_retention_pct": 10
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.